Volume 25, Issue 2 (Iranian South Medical Journal 2022)                   Iran South Med J 2022, 25(2): 105-113 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Esmaeeli A, Montazeri H, Keshavarzi S, Tanha K, Seyedabadi M. Immunohistochemical Comparison of p53 Expression, Intensity and Distribution in Different Papillary Urothelial Cancers. Iran South Med J 2022; 25 (2) :105-113
URL: http://ismj.bpums.ac.ir/article-1-1612-en.html
1- Department of Pathology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
2- Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran
3- Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4- Department of Pathology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
Department of Toxicology and Pharmacology, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Pharmaceutical Sciences Research Center, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran , seyedabadi1981@gmail.com
Abstract:   (461 Views)
Background: Given the importance of differential diagnosis of different papillary urothelial cancers, expression, intensity and distribution of p53 were evaluated in different bladder cancers using immunohistochemistry.
Materials and Methods: In a retrospective study, archived samples of patients with different papillary urothelial cancers in Shohaday-e-Khalij Fars Hospital were selected. The samples were grouped according to the reported diagnosis into papilloma, low-malignant potential papillary tumors, low-grade papillary carcinoma, and high-grade papillary carcinoma. The samples were then immunohistochemically stained for p53. 
Results: The majority of patients with papillary urothelial carcinoma were positive for p53. However, they were different in terms of intensity (p<0.001) and distribution (p<0.01). Low-malignant potential and low-grade malignant samples demonstrated low levels of p53 expression, whereas high-grade malignant samples exhibited high levels of its expression. Comparison of p53 distribution revealed focal expression in low-malignant potential group and diffused expression in malignant groups.
Conclusion: The results of this study suggest p53 expression, intensity and distribution as a useful marker for differential diagnosis and therapeutic management of different urothelial cancers.
Full-Text [PDF 449 kb]   (146 Downloads)    
Type of Study: Original | Subject: Clinical Laboratory Pathology
Received: 2021/11/6 | Accepted: 2021/11/29 | Published: 2022/09/26

1. Stewart BW, Wild CP. World Cancer Report 2014. Geneva, Switzerland: 444-465.
2. Hahn NM. Cancer of the Bladder and Urinary Tract. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 20e. McGraw Hil, 2018. Accessed April 24, 2022. [Article]
3. Pulciani S, Santos E, Lauver AV, et al. Oncogenes In Human Tumor Cell Lines: Molecular Cloning Of A Transforming Gene From Human Bladder Carcinoma Cells. Proc Natl Acad Sci USA 1982; 79(9): 2845-9. [DOI]
4. Sidransky D, Messing E. Molecular Genetics And Biochemical Mechanisms In Bladder Cancer. Oncogenes, Tumor Suppressor Genes, And Growth Factors. Urol Clin North Am 1992; 19(4): 629-39. [PubMed]
5. Cooper GM, Hausman RE, Hausman RE. The Cell: A Molecular Approach, 8e, Sinauer Associates: Sunderland, MA, 2019: 713-777. [Article]
6. Du J, Wang SH, Yang Q, et al. p53 Status Correlates With The Risk Of Progression In Stage T1 Bladder Cancer: A Meta-Analysis. World J Surg Onc 2016; 14: 137. [DOI]
7. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 Tumor Suppressor Gene: Clues To Cancer Etiology And Molecular Pathogenesis. Cancer Res 1994; 54(18): 4855-78. [PubMed]
8. Joerger AC, Fersht AR. Structural Biology Of The Tumor Suppressor p53. Annu Rev Biochem 2008; 77: 557-82. [DOI]
9. Rizzotto D, Englmaier L, Villunger A. At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity. Int J Mol Sci 2021; 22(19): 10883. [DOI]
10. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50(1): 7-33. [DOI]
11. Bargonetti J, Manfredi JJ. Multiple Roles Of The Tumor Suppressor p53. Curr Opin Oncol 2002; 14(1): 86-91. [DOI]
12. Aljabery F, Shabo I, Gimm O, et al. The Expression Profile of p14, p53 and p21 in Tumour Cells Is Associated With Disease-Specific Survival and the Outcome Of Postoperative Chemotherapy Treatment In Muscle-Invasive Bladder Cancer. Urol Oncol 2018; 36(12): 530.e7-530.e18. [DOI]
13. Heim S, Mitelman F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, 4e. WileyBlackwell, 2015: 113-145. [Article]
14. Goebell PJ, Groshen SG, Schmitz-Drager BJ, et al. p53 Immunohistochemistry In Bladder Cancer--A New Approach To An Old Question. Urol Oncol 2010; 28(4): 377-88. [DOI]
15. Nakopoulou L, Constantinides C, Papandropoulos J, et al. Evaluation of Overexpression of p53 Tumor Suppressor Protein In Superficial And Invasive Transitional Cell Bladder Cancer: Comparison With DNA Ploidy. Urology 1995; 46(3): 334-40. [DOI]
16. Wu CS, Pollack A, Czerniak B, et al. Prognostic Value of p53 In Muscle-Invasive Bladder Cancer Treated With Preoperative Radiotherapy. Urology 1996; 47(3): 305-10. [DOI]
17. Fromont G, Roupret M, Amira N, et al. Tissue Microarray Analysis Of The Prognostic Value of E-cadherin, Ki67, p53, p27, survivin and MSH2 Expression In Upper Urinary Tract Transitional Cell Carcinoma. Eur Urol 2005; 48(5): 764-70. [DOI]
18. Hodgson A, Xu B, Downes MR. p53 Immunohistochemistry In High-Grade Urothelial Carcinoma Of The Bladder Is Prognostically Significant. Histopathology 2017; 71(2): 296-304. [DOI]
19. Alexander RE, Williamson SR, Richey J, et al. The Expression Patterns of p53 and p16 and an Analysis Of A Possible Role Of HPV In Primary Adenocarcinoma Of The Urinary Bladder. PLoS One 2014; 9(4): e95724. [DOI]
20. Horstmann M, Witthuhn R, Falk M, et al. Gender-Specific Differences In Bladder Cancer: A Retrospective Analysis. Gend Med 2008; 5(4): 385-94. [DOI]
21. Rafiemanesh H, Lotfi Z, Bakhtazad S, et al. The Epidemiological And Histological Trend Of Bladder Cancer In Iran. J Cancer Res Ther 2018; 14(3): 532-6. [DOI]
22. Cheng L, Zhang S, Davidson DD, et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol 2009; 5(6): 843-57. [Article]
23. Lutzeyer W, Rübben H, Dahm H. Prognostic Parameters In Superficial Bladder Cancer: An Analysis Of 315 Cases. J Urol 1982; 127(2): 250-2. [DOI]
24. Prout Jr GR, Barton BA, Griffin PP, et al. Treated history of noninvasive grade 1 transitional cell carcinoma. 1992;148(5):1413-9. [DOI]
25. Kurth K, Bouffioux C, Sylvester R, et al. MJEu. Treatment Of Superficial Bladder Tumors: Achievements And Needs. 2000; 37(Suppl. 3): 1-9. [DOI]
26. Kiemeney LA, Moret NC, Witjes JA, et al. Familial Transitional Cell Carcinoma Among The Population Of Iceland. J Urol 1997; 157(5): 1649-51. [PubMed]
27. SafariChaleshtori J, Moradi M T, Farokhi E, et al. Detection of mutations in exons 5-8 of the P53 gene in gastric cancer samples using PCR-SSCP in Chaharmahal va Bakhtiari province 2006-2007. J Shahrekord Univ Med Sci. 2009; 11(3): 61-69. [Article]
28. Tetu B, Fradet Y, Allard P, et al. Prevalence And Clinical Significance of HER-2/neu, p53 and Rb Expression In Primary Superficial Bladder Cancer. J Urol 1996; 155(5): 1784-8. [PubMed]
29. Lorenzo-Romero JG, Salinas-Sanchez AS, Gimenez-Bachs JM, et al. Prognostic Implications of p53 Gene Mutations In Bladder Tumors. J Urol 2003; 169(2): 492-9. [DOI]
30. Levine AJ, Momand J, Finlay CA. The p53 Tumour Suppressor Gene. Nature 1991; 351(6326): 453-6. [DOI]
31. Esrig D, Spruck 3rd CH, Nichols PW, et al. p53 Nuclear Protein Accumulation Correlates With Mutations In The p53 Gene, Tumor Grade, And Stage In Bladder Cancer. Am J Pathol 1993; 143(5): 1389-97. [PubMed]
32. Asgari M, Noori S. P53 Over Expression In Transitional Cell Carcinoma Of Bladder. Razi J Med Sci 2002; 9(29): 250-4. (Persian) [Article]
33. Saffari Chaleshtary J, Moradi Mt, Farrokhi E, et al. Study of P53 gene mutations in promoter and exons 2-4 and 9-11 in patient with gastric cancer by PCR-SSCP in Chaharmahal Va Bakhtiari province. Iranian South Medical Journal 2011; 14(4): 220-9. [Article]
34. Goebell PJ, Groshen SG, Schmitz-Dräger BJ. p53 immunohistochemistry in bladder cancer-- a new approach to an old question. Urologic oncology 2010; 28(4): 377-88. [DOI]
35. Papadogianni D, Soulitzis N, Delakas D, et al. Expression of p53 Family Genes In Urinary Bladder Cancer: Correlation With Disease Aggressiveness And Recurrence. Tumour Biol 2014; 35(3): 2481-9. [DOI]
36. Wang ZP, Chen SY, Tian Y. Wild-type p53-Induced Phosphatase 1 Is A Prognostic Marker And Therapeutic Target In Bladder Transitional Cell Carcinoma. Oncol Lett 2017; 13(2): 875-80. [DOI]
37. Zaker Hosseini M, Naeimi S, Moradinasab M, et al. Codon 72 Polymorphism of TP53 Gene in Cervical Biopsies with Abnormal Histology in Bushehr Province. Iran South Med J 2018; 21(1): 19-28. [Article]

Send email to the article author

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | ISMJ

Designed & Developed by: Yektaweb